UBT251
UBT251 Injection Phase II Clinical Study (CKD)
The United Bio-Technology (Hengqin) Co · Phase 2 · Recruiting · Enrollment 180
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 2.0 mg group | n/r | n/r | n/r | n/r | n/r |
| 4.0 mg group | n/r | n/r | n/r | n/r | n/r |
| 6.0 mg group | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.